Market Cap 1.99B
Revenue (ttm) 166.03M
Net Income (ttm) -84.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -50.95%
Debt to Equity Ratio 15.06
Volume 610,866
Avg Vol 544,692
Day's Range N/A - N/A
Shares Out 29.06M
Stochastic %K 36%
Beta 0.92
Analysts Strong Sell
Price Target $82.25

Company Profile

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgeries. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. Establishmen...

Industry: Medical Devices
Sector: Healthcare
Phone: 506 2434 2400
Address:
Building B23 and B25, Coyol Free Zone, Alajuela, Costa Rica
Lambster2
Lambster2 Jan. 12 at 1:35 PM
$ESTA We got the positive preannounce. JPM on 1/14 80s on their way Cash flow positive by year end. 120-150 longer term.
1 · Reply
Lambster2
Lambster2 Jan. 12 at 1:07 PM
$ESTA “We had an excellent finish to 2025, with record quarterly revenue,” said Peter Caldini, Establishment Labs’ Chief Executive Officer. “Growth will continue in 2026 as our business accelerates towards being the industry standard. We continue to have positive adjusted EBITDA, and our cash position reflects our success in managing and improving the business. We expect to turn free cash flow positive later this year, and our operating leverage will become very evident in 2026 and beyond. I look forward to our meetings at the J.P. Morgan Healthcare Conference this week and presenting our full 2025 results on our February earnings call.”
1 · Reply
Lambster2
Lambster2 Jan. 12 at 1:05 PM
$ESTA Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 January 12, 2026 Revenue for the quarter ended December 31, 2025 is expected to be between $64.0 million and $65.0 million, including between $17.0 million and $17.5 million from Motiva sales in the United States. Revenue for fiscal year 2025 is expected to be in the range of $210.5 million to $211.5 million, representing growth of approximately 27% over 2024, including between $45.4 million and $45.9 million from Motiva sales in the United States. The Company’s year-end 2025 cash position is expected to be approximately $75.5 million, an increase of $4.8 million from the end of the third quarter of 2025. https://establishmentlabs2023cr.q4web.com/press-releases/press-releases-details/2026/Establishment-Labs-Announces-Preliminary-Unaudited-Financial-Results-for-Fourth-Quarter-and-Fiscal-Year-2025/default.aspx
0 · Reply
StardustTrader
StardustTrader Jan. 9 at 3:52 PM
$ESTA establishing new range.
0 · Reply
Lambster2
Lambster2 Jan. 7 at 3:51 PM
$ESTA Once again Schwab requiring a call to a broker to purchase. WTH
2 · Reply
Lambster2
Lambster2 Jan. 6 at 6:04 PM
$ESTA That's better. On to 80s
1 · Reply
Lambster2
Lambster2 Jan. 6 at 12:15 PM
$ESTA Rolled IREN and ETHU profits in to more ESTA yesterday. Second largest holding behind TMDX. I think we get a positive preannounce on 1/14 at JPM then on to 80s
1 · Reply
Bio_Pharm
Bio_Pharm Jan. 5 at 11:35 PM
$ESTA I've seen this with another stock years ago. It will dip now until the next event then go past previous highs.
1 · Reply
Lambster2
Lambster2 Jan. 5 at 4:13 PM
$ESTA Technically may see 48-52 Wait mode. Positive preannounce at JPM on 1/14 and it breaks out to 80s imo
0 · Reply
Lambster2
Lambster2 Jan. 5 at 4:07 PM
$ESTA Adding here under 65. Oversold
0 · Reply
Latest News on ESTA
Establishment Labs Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 8:00 AM EST - 2 months ago

Establishment Labs Reports Third Quarter 2025 Financial Results


Establishment Labs Hosting Investor Day on June 12

Jun 11, 2025, 7:07 PM EDT - 7 months ago

Establishment Labs Hosting Investor Day on June 12


Establishment Labs Reports First Quarter 2025 Financial Results

May 7, 2025, 4:00 PM EDT - 8 months ago

Establishment Labs Reports First Quarter 2025 Financial Results


Establishment Labs Launches Preservé™

Feb 18, 2025, 8:00 AM EST - 11 months ago

Establishment Labs Launches Preservé™


Establishment Labs Announces CEO Transition

Jan 13, 2025, 8:00 AM EST - 1 year ago

Establishment Labs Announces CEO Transition


Lambster2
Lambster2 Jan. 12 at 1:35 PM
$ESTA We got the positive preannounce. JPM on 1/14 80s on their way Cash flow positive by year end. 120-150 longer term.
1 · Reply
Lambster2
Lambster2 Jan. 12 at 1:07 PM
$ESTA “We had an excellent finish to 2025, with record quarterly revenue,” said Peter Caldini, Establishment Labs’ Chief Executive Officer. “Growth will continue in 2026 as our business accelerates towards being the industry standard. We continue to have positive adjusted EBITDA, and our cash position reflects our success in managing and improving the business. We expect to turn free cash flow positive later this year, and our operating leverage will become very evident in 2026 and beyond. I look forward to our meetings at the J.P. Morgan Healthcare Conference this week and presenting our full 2025 results on our February earnings call.”
1 · Reply
Lambster2
Lambster2 Jan. 12 at 1:05 PM
$ESTA Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 January 12, 2026 Revenue for the quarter ended December 31, 2025 is expected to be between $64.0 million and $65.0 million, including between $17.0 million and $17.5 million from Motiva sales in the United States. Revenue for fiscal year 2025 is expected to be in the range of $210.5 million to $211.5 million, representing growth of approximately 27% over 2024, including between $45.4 million and $45.9 million from Motiva sales in the United States. The Company’s year-end 2025 cash position is expected to be approximately $75.5 million, an increase of $4.8 million from the end of the third quarter of 2025. https://establishmentlabs2023cr.q4web.com/press-releases/press-releases-details/2026/Establishment-Labs-Announces-Preliminary-Unaudited-Financial-Results-for-Fourth-Quarter-and-Fiscal-Year-2025/default.aspx
0 · Reply
StardustTrader
StardustTrader Jan. 9 at 3:52 PM
$ESTA establishing new range.
0 · Reply
Lambster2
Lambster2 Jan. 7 at 3:51 PM
$ESTA Once again Schwab requiring a call to a broker to purchase. WTH
2 · Reply
Lambster2
Lambster2 Jan. 6 at 6:04 PM
$ESTA That's better. On to 80s
1 · Reply
Lambster2
Lambster2 Jan. 6 at 12:15 PM
$ESTA Rolled IREN and ETHU profits in to more ESTA yesterday. Second largest holding behind TMDX. I think we get a positive preannounce on 1/14 at JPM then on to 80s
1 · Reply
Bio_Pharm
Bio_Pharm Jan. 5 at 11:35 PM
$ESTA I've seen this with another stock years ago. It will dip now until the next event then go past previous highs.
1 · Reply
Lambster2
Lambster2 Jan. 5 at 4:13 PM
$ESTA Technically may see 48-52 Wait mode. Positive preannounce at JPM on 1/14 and it breaks out to 80s imo
0 · Reply
Lambster2
Lambster2 Jan. 5 at 4:07 PM
$ESTA Adding here under 65. Oversold
0 · Reply
Thestockguy77
Thestockguy77 Jan. 5 at 3:31 PM
$ESTA someone is shaking the tree
0 · Reply
Lambster2
Lambster2 Jan. 5 at 2:35 PM
$ESTA Added at 69. Looking for positive preannounce in January, possibly at JPM Conf.
0 · Reply
Thestockguy77
Thestockguy77 Jan. 2 at 9:19 PM
$ESTA a little gift today. Added more with some extra cash I had after selling at the end of the year.
0 · Reply
Lambster2
Lambster2 Jan. 2 at 8:57 PM
$ESTA Online buy order now working at Schwab. No broker assist via call required. Odd.
0 · Reply
TriGuy8542
TriGuy8542 Jan. 2 at 8:55 PM
$ESTA bought a tiny amount more (60 Shares) and sold two calls today. If the company does well and they are exercised, post tax I’ll make 5.4% gains accounting for taxes, which keeps me above the S&P 500 if they hit. If not, I was just give $300 and I keep shares in a company I like and will continue selling calls to lower cost basis.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 7:25 PM
$ESTA Current Stock Price: $69.10 Contracts to trade: $70 ESTA Jan 16 2026 Call Entry: $2.95 Exit: $4.66 ROI: 58% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Lambster2
Lambster2 Jan. 2 at 6:09 PM
$ESTA Why is Schwab requiring by phone only buy orders?
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jan. 2 at 5:15 PM
$ESTA I was looking at the options there’s millions on the call and put side… Meaning is the future movement is up for grabs …I would tread lightly since this has had a big run w NO earnings yet
0 · Reply
Lambster2
Lambster2 Dec. 31 at 7:53 PM
$ESTA BTIG raises PT from 81 to 86
0 · Reply
Lambster2
Lambster2 Dec. 31 at 1:08 PM
$ESTA Annual J.P. Morgan Healthcare Conference December 31, 2025 NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. https://establishmentlabs2023cr.q4web.com/press-releases/press-releases-details/2025/Establishment-Labs-to-Present-at-44th-Annual-J-P--Morgan-Healthcare-Conference/default.aspx
0 · Reply
TriGuy8542
TriGuy8542 Dec. 30 at 9:52 PM
$ESTA purchased 140 shares today
0 · Reply
Lambster2
Lambster2 Dec. 30 at 7:49 PM
$ESTA Cowen ups PT to 88 Establishment Labs (NASDAQ: ESTA) Buy (1) ESG Score: 45/100 Price Target: $88.00 (Prior $77.00) ESTA Files Breast Recon PMA; US Launch Update Signals Continued Share Gains THE TD COWEN INSIGHT Yesterday, ESTA announced the PMA submission of Motiva implants to FDA for approval in both primary and revision breast recon indications. ESTA will be able to lever the PMA modules submitted for the primary and revision augmentation filing so the FDA will now review the recon clinical data module. Management also signaled that the US Motiva launch momentum continues. Reiterate Buy rating.
0 · Reply